Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

Key Takeaway: Compass Pathways plc will participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company will host a fireside chat at 1:00 pm ET, which will be available via a live audio webcast. Compass is focused on developing innovative treatments for mental health, including its investigational psilocybin treatment, COMP360.
Price reaction · baseline $13.81 (2026-09-15 close) · hit pre-market · clean, no other CMPS news in the window
day 0 close
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent neuropsychiatry summit highlights company engagement.
  • Focus on innovative treatments for mental health conditions shows commitment to patient care.
  • COMP360 psilocybin has received Breakthrough Therapy designation from the FDA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+172%
120-day peak, hindsight
Typical move
8.6%
average across 3 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
COMP360
Phase 3 · Treatment Resistant Depression

Full Press Release Details

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET.
A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ
A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website.
About Compass Pathways
We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.
Compass is headquartered in London, UK, with a U.S. office in New York.
We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Frequently Asked Questions

When is the TD Cowen Neuropsychiatry Summit?

The summit will take place on September 23, 2026.

What will Compass Pathways do at the summit?

Compass Pathways will participate in a fireside chat at 1:00 pm ET.

How can I access the fireside chat?

The fireside chat will be available via a live audio webcast.

What is COMP360?

COMP360 is an investigational psilocybin treatment for treatment-resistant depression and PTSD.

What designations has COMP360 received?

COMP360 has Breakthrough Therapy designation from the FDA and ILAP designation in the UK.

Last updated: Sep 16, 2026